Physician profile
Sujote David
NPI 1891797965
$1,960.14
in general payments reported to CMS, 2019-2025
16 companies · $337 in 2025
The $337 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $125 · 2021: $250 · 2022: $362 · 2023: $310 · 2024: $178 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $823.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $419.06 | 2019-2025 | Clareon, Rocklatan, Argos |
| Allergan, INC. | $221.55 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $207.78 | 2022-2025 | Vyzulta, Infuse, Miebo |
| Sun Pharmaceutical Industries INC. | $182.95 | 2019-2023 | Cequa |
| Abbvie INC. | $131.29 | 2023-2025 | Xen Glaucoma Treatment System |
| Aerie Pharmaceuticals, INC. | $127.87 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $121.29 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.52 | 2019-2021 | |
| Thea Pharma INC. | $92.32 | 2023-2025 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $90.09 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $71.88 | 2019-2022 | |
| Horizon Therapeutics Plc | $71.19 | 2022-2023 | Tepezza |
| Sight Sciences, INC. | $35.80 | 2020-2023 | Omni Surgical System |
| Oyster Point Pharma, INC. | $32.88 | 2024 | Tyrvaya |
| Glaukos Corporation | $30.71 | 2019-2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $22.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujote David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.